{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:26:04Z","timestamp":1791296764817,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5,15]]},"DOI":"10.2146\/ajhp090247","type":"journal-article","created":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T16:28:13Z","timestamp":1274113693000},"page":"793-797","source":"Crossref","is-referenced-by-count":87,"title":["Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma"],"prefix":"10.1093","volume":"67","author":[{"given":"Shannon A.","family":"Kavanaugh","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Wisconsin (UW), Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"White","sequence":"additional","affiliation":[{"name":"School of Pharmacy, UW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Kolesar","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Paul P. Carbone Comprehensive Cancer Center, UW"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041104254651600_b1-0670793","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.hoc.2008.07.014","article-title":"Cutaneous T-cell lymphoma","volume":"22","author":"Lansigan","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"key\n\t\t\t\t2019041104254651600_b2-0670793","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"key\n\t\t\t\t2019041104254651600_b3-0670793","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1200\/JCO.2001.19.3.779","article-title":"Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides","volume":"19","author":"De Coninck","year":"2001","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104254651600_b4-0670793","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t2019041104254651600_b5-0670793","volume-title":"Zolinza (vorinostat) full prescribing information","year":"2006"},{"key":"key\n\t\t\t\t2019041104254651600_b6-0670793","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t2019041104254651600_b7-0670793","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1101\/gad.12.5.599","article-title":"Histone acetylation and transcriptional regulatory mechanisms","volume":"12","author":"Struhl","year":"1998","journal-title":"Genes Dev"},{"key":"key\n\t\t\t\t2019041104254651600_b8-0670793","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1101\/gad.1232504","article-title":"Epigenetics and cancer","volume":"18","author":"Lund","year":"2004","journal-title":"Genes Dev"},{"key":"key\n\t\t\t\t2019041104254651600_b9-0670793","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.biocel.2008.05.026","article-title":"Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A","volume":"41","author":"Codd","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"key\n\t\t\t\t2019041104254651600_b10-0670793","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","article-title":"Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?","volume":"4","author":"Johnstone","year":"2003","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t2019041104254651600_b11-0670793","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104254651600_b12-0670793","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1592\/phco.28.6.755","article-title":"Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?","volume":"28","author":"Perera","year":"2008","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041104254651600_b13-0670793","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.tpj.6500012","article-title":"Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy","volume":"1","author":"Pullarkat","year":"2001","journal-title":"Pharmacogenomics J"},{"key":"key\n\t\t\t\t2019041104254651600_b14-0670793","unstructured":"ClinicalTrials.gov. Vorinostat trials. www.clinicaltrials.gov\/ct2\/results?term=vorinostat (accessed 2009 May 7)."},{"key":"key\n\t\t\t\t2019041104254651600_b15-0670793","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104254651600_b16-0670793","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104254651600_b17-0670793","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events, version 4.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev4.pdf (accessed 2009 Jul 7)."},{"key":"key\n\t\t\t\t2019041104254651600_b18-0670793","first-page":"23","article-title":"Vorinostat (Zolinza) for cutaneous T-cell lymphoma","volume":"49","year":"2007","journal-title":"Med Lett Drugs Ther"},{"key":"key\n\t\t\t\t2019041104254651600_b19-0670793","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/bdrb.20104","article-title":"Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits","volume":"80","author":"Wise","year":"2007","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"key\n\t\t\t\t2019041104254651600_b20-0670793","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O\u2019Connor","year":"2006","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104254651600_b21-0670793","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1158\/1078-0432.CCR-06-1802","article-title":"A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer","volume":"12","author":"Rubin","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041104254651600_b22-0670793","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t2019041104254651600_b23-0670793","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104254651600_b24-0670793","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdn031","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma","volume":"19","author":"Crump","year":"2008","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019041104254651600_b25-0670793","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10637-008-9131-6","article-title":"Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer","volume":"26","author":"Vansteenkiste","year":"2008","journal-title":"Invest New Drugs"},{"key":"key\n\t\t\t\t2019041104254651600_b26-0670793","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","article-title":"A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study","volume":"109","author":"Modesitt","year":"2008","journal-title":"Gynecol Oncol"},{"key":"key\n\t\t\t\t2019041104254651600_b27-0670793","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1210\/jc.2008-1631","article-title":"Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine- refractory thyroid carcinoma","volume":"94","author":"Woyach","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041104254651600_b28-0670793","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10637-007-9075-2","article-title":"Phase II trial of the histone deacetylase inhibitor vorinostat (zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and\/or metastatic head and neck cancer","volume":"26","author":"Blumenschein","year":"2008","journal-title":"Invest New Drugs"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/67\/10\/793\/28344065\/ajhp0793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T07:09:26Z","timestamp":1559113766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/67\/10\/793\/5129902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,15]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,5,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp090247","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,5,15]]},"published":{"date-parts":[[2010,5,15]]}}}